Searcharxiv⌕ Search

arXiv subjects

Lingli Yang

Publications and source records attributed to Lingli Yang.

9 recordsLinked to original sources

Calibrated Transfer Learning for Survival Prediction and Treatment Inference

Historical survival data can improve prediction in a cohort with few events, but prognostic differences can make borrowing harmful. To borrow while adapting, we propose calibrated transfer learning for the Cox model, in which a historical risk function enters the target analysis as a fixed offset with a prespecified correction for changing covariate effects and a separate baseline hazard. Calibration removes historical error in the correction space exactly, so only the remaining error governs the prediction rate, for any bounded learner. Accurate prediction does not, however, ensure valid treatment inference. In randomized trials, the remaining error biases the conditional treatment coefficient, because a treatment effect changes the prognostic composition of later risk sets. We characterize this bias and its sharp worst-case direction, and we introduce a cross-fitted projected score that removes it at first order and leaves only a second-order bias when a fixed error lies in its dictionary. A historical learning bound separates approximation, sampling, and optimization error. In simulations, calibration improves prediction when the historical risk is well learned, and the projected score restores interval coverage under drift outside the correction, also at a hazard ratio of 0.7. In a retrospective transfer between the POPLAR and OAK lung cancer trials, selected corrections reduce the integrated Brier score by 4.3\% relative to ridge-penalized clinical Cox with 100 training patients, without improving treatment precision.

stat.ME↗

Direct Learning of Treatment-Benefit Rankings for Restricted Mean Survival Time in Randomized Trials with Censoring

In precision medicine, treatment decisions often depend more on identifying which patients are most likely to benefit from treatment than on accurately estimating benefit for every patient. However, existing methods estimate patient-specific treatment effects and derive patient rankings as a secondary step. We propose a direct ranking approach for conditional RMST treatment benefit in randomized trials with right-censored outcomes. We first construct a censoring-adjusted orthogonal RMST pseudo-outcome whose conditional expectation equals the true conditional RMST difference. Then, we compare patients pairwise and optimize a smooth ranking loss that directly targets treatment-benefit ordering. The pairwise criterion incorporates orthogonal corrections for estimation of the event and censoring distributions. We show that the population minimizer of the proposed loss induces the same ordering as the true conditional RMST treatment benefit and that the resulting estimating equation is Neyman-orthogonal to nuisance survival and censoring models. In simulation studies with nonlinear treatment-effect heterogeneity and moderate to heavy censoring, the proposed approach improved rank correlation and treatment-benefit enrichment relative to both plug-in RMST estimation and regression of the same RMST pseudo-outcome. Application to a randomized breast cancer trial demonstrated improved identification of patients with greater treatment benefit. In conclusion, the proposed framework combines orthogonal survival learning with pairwise ranking and may be particularly useful in precision medicine settings where treatment prioritization and patient selection are the primary goals.

stat.ME↗

Adaptive Sampling of Costly Outcomes in Randomized Clinical Trials

In some randomized trials the primary outcome is costly or slow to measure, while auxiliary variables that predict it are available for everyone. The outcome can then be measured in a probability sample. We study an adaptive design in which the statistician who selects outcomes to measure is blinded to treatment assignment. Outcomes from an initial random sample are used to fit pooled models for the outcome and its residual variance. These set the sampling probabilities for the remaining participants and may be refitted as outcomes accumulate. After unblinding, arm means are estimated by augmented inverse probability weighting. The estimator is unbiased for the complete-data treatment difference for any working models, and a martingale central limit theorem gives Wald intervals under repeated updating. We bound the variance lost by estimating the sampling rule. The bound is linear in the error of the fitted residual variance, quadratic when the optimal probabilities are not truncated, and relates the initial sample size to the learning rate of the models. Relative to designs using treatment assignment, the blinded design loses a term due to unequal residual variances in the two arms and a term due to the conditional treatment effect, which is second order near the null. In simulations, coverage was near nominal. Adaptive sampling was 12% to 34% more efficient than simple random sampling and needed 10% to 26% fewer measured outcomes for the same precision. In a resampling study of an antifungal trial, adaptive sampling reduced the sampling variance by 39%.

stat.ME↗

Information Borrowing for Cox Regression with an Auxiliary Outcome

Time-to-event outcomes are often collected together with auxiliary outcomes that may provide additional information about baseline risk. We develop a semiparametric approach for incorporating such information into Cox regression without specifying a joint likelihood. The survival outcome follows a Cox proportional hazards model and a continuous auxiliary outcome follows a partially linear model, with separate nonparametric baseline covariate effects linked through a quadratic penalty. When these effects coincide and the outcome scores satisfy the information identities and a first-order orthogonality condition, we derive the sandwich covariance of the penalized estimator and show that, for any fixed penalty level, the asymptotic variance of the Cox regression estimator is no greater than that under separate estimation. We further characterize departures from the shared-effect setting. Local differences of order \(n^{-1/2}\) induce an explicit mean shift in the limiting distribution, yielding a direct bias--variance trade-off, whereas fixed differences generally alter the population target under nonvanishing penalization. These results motivate an adaptive penalty that borrows information when the fitted covariate effects are close and approaches separate estimation when a persistent difference is detected. Simulations and a real world data analysis demonstrate the validity and effectiveness of the proposed method.

stat.ME↗

Worst-Case Win Ratios Under Partially Specified Outcome Hierarchies

Win statistics require a prespecified outcome hierarchy. Clinical teams sometimes agree only on the highest priority outcome, leaving the order of lower priority outcomes unresolved, and clinically meaningful thresholds may be specified as ranges. Separate sensitivity analyses describe how the results change. A single inference for the full set of planned analyses is generally absent. We define the estimand as the smallest net benefit among the comparison rules allowed by the protocol or statistical analysis plan. Each rule uses the usual two-sample U-statistic. Large-sample results are developed for a finite list of rules and for a continuous threshold range. Inversion of an intersection-union test gives a one-sided lower confidence bound, with no multiplicity adjustment for the single claim that every individual net benefit is positive. Simulations show valid one-sided coverage and illustrate the gap between a favorable result for one selected hierarchy and a favorable result across all prespecified hierarchies. An application to ACTG 175 shows how the ordering of laboratory outcomes can affect the strength of the conclusion. A further example identifies an unfavorable threshold that is missed by a sparse grid.

stat.ME↗

Detection of LUAD-Associated Genes Using Wasserstein Distance in Multi-Omics Feature Selection

Lung adenocarcinoma (LUAD) is characterized by substantial genetic heterogeneity, posing challenges in identifying reliable biomarkers for improved diagnosis and treatment. Tumor Mutational Burden (TMB) has traditionally been regarded as a predictive biomarker, given its association with immune response and treatment efficacy. In this study, we treated TMB as a response variable to identify genes highly correlated with it, aiming to understand its genetic drivers. We conducted a thorough investigation of recent feature selection methods through extensive simulations, selecting PC-Screen, DC-SIS, and WD-Screen as top performers. These methods handle multi-omics structures effectively, and can accommodate both categorical and continuous data types at the same time for each gene. Using data from The Cancer Genome Atlas (TCGA) via cBioPortal, we combined copy number alteration (CNA), mRNA expression and DNA methylation data as multi-omics predictors and applied these methods, selecting genes consistently identified across all three methods. 13 common genes were identified, including HSD17B4, PCBD2, which show strong associations with TMB. Our multi-omics strategy and robust feature selection approach provide insights into the genetic determinants of TMB, with implications for targeted LUAD therapies.

stat.AP↗

Deep Feature Screening: Feature Selection for Ultra High-Dimensional Data via Deep Neural Networks

The applications of traditional statistical feature selection methods to high-dimension, low sample-size data often struggle and encounter challenging problems, such as overfitting, curse of dimensionality, computational infeasibility, and strong model assumption. In this paper, we propose a novel two-step nonparametric approach called Deep Feature Screening (DeepFS) that can overcome these problems and identify significant features with high precision for ultra high-dimensional, low-sample-size data. This approach first extracts a low-dimensional representation of input data and then applies feature screening based on multivariate rank distance correlation recently developed by Deb and Sen (2021). This approach combines the strengths of both deep neural networks and feature screening, and thereby has the following appealing features in addition to its ability of handling ultra high-dimensional data with small number of samples: (1) it is model free and distribution free; (2) it can be used for both supervised and unsupervised feature selection; and (3) it is capable of recovering the original input data. The superiority of DeepFS is demonstrated via extensive simulation studies and real data analyses.

stat.ML↗

Multivariate Rank-Based Analysis of Multiple Endpoints in Clinical Trials: A Global Test Approach

Clinical trials often involve the assessment of multiple endpoints to comprehensively evaluate the efficacy and safety of interventions. In the work, we consider a global nonparametric testing procedure based on multivariate rank for the analysis of multiple endpoints in clinical trials. Unlike other existing approaches that rely on pairwise comparisons for each individual endpoint, the proposed method directly incorporates the multivariate ranks of the observations. By considering the joint ranking of all endpoints, the proposed approach provides robustness against diverse data distributions and censoring mechanisms commonly encountered in clinical trials. Through extensive simulations, we demonstrate the superior performance of the multivariate rank-based approach in controlling type I error and achieving higher power compared to existing rank-based methods. The simulations illustrate the advantages of leveraging multivariate ranks and highlight the robustness of the approach in various settings. The proposed method offers an effective tool for the analysis of multiple endpoints in clinical trials, enhancing the reliability and efficiency of outcome evaluations.

stat.ME↗

On the Confidence Intervals in Bioequivalence Studies

A bioequivalence study is a type of clinical trial designed to compare the biological equivalence of two different formulations of a drug. Such studies are typically conducted in controlled clinical settings with human subjects, who are randomly assigned to receive two formulations. The two formulations are then compared with respect to their pharmacokinetic profiles, which encompass the absorption, distribution, metabolism, and elimination of the drug. Under the guidance from Food and Drug Administration (FDA), for a size-$α$ bioequivalence test, the standard approach is to construct a $100(1-2α)\%$ confidence interval and verify if the confidence interval falls with the critical region. In this work, we clarify that $100(1-2α)\%$ confidence interval approach for bioequivalence testing yields a size-$α$ test only when the two one-sided tests in TOST are ``equal-tailed''. Furthermore, a $100(1-α)\%$ confidence interval approach is also discussed in the bioequivalence study.

stat.ME↗